topotecan has been researched along with Breast Cancer in 69 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (18.84) | 18.2507 |
| 2000's | 40 (57.97) | 29.6817 |
| 2010's | 15 (21.74) | 24.3611 |
| 2020's | 1 (1.45) | 2.80 |
| Authors | Studies |
|---|---|
| Imai, Y; Sugimoto, Y; Tsukahara, S; Tsuruo, T; Ueda, K | 1 |
| Bruick, RK; Hossain, CF; Mohammed, KA; Nagle, DG; Zhang, L; Zhou, YD | 1 |
| Chen, TC; Chen, YL; Cheng, CM; Hsu, CY; Lu, YJ; Tseng, CH; Tso, HC; Tzeng, CC | 1 |
| Bao, Y; Guo, J; Li, Y; Sun, W; Wang, J; Wang, Q; Zhang, S; Zhang, Y | 1 |
| Anderson, SK; Colon-Otero, G; Dixon, JG; Hebenstreit, K; Jaeckle, KA; Moreno-Aspitia, A; Patel, TA; Perez, EA; Reddy, SL | 1 |
| Ahmad, N; Banala, VT; Barnwal, P; Dwivedi, M; Kalleti, N; Mishra, PR; Mitra, K; Mittapelly, N; Pandey, G; Rath, SK; Sharma, S; Shukla, RP; Trivedi, R; Urandur, S | 1 |
| Banerjee, R; Prasad, C | 1 |
| Balslev, E; Brünner, N; Kümler, I; Nielsen, DL; Stenvang, J | 1 |
| Fleming, GF; Lukas, RV; Salgia, S | 1 |
| Cao, KI; Kirova, YM | 1 |
| Bernhardt, G; Brockhoff, G; Buschauer, A; Huber, S; Wege, AK | 1 |
| Du, D; Lai, Y; Li, H; Lin, S; Lyu, X; Sun, L; Wang, Y; Yin, H; Yu, J; Yuan, S; Zhang, L | 1 |
| Adjei, AA; Erlichman, C; Felten, SJ; Flatten, KS; Friedman, R; Gálvez-Peralta, M; Gilmer, TM; Jewell, RC; Kaufmann, SH; Koch, KM; Mandrekar, S; Molina, JR; Mullin, RJ; Reid, JM; Rubin, SD | 1 |
| Enomoto, T; Hayashi, K; Iizuka, M; Kuranami, M; Nakakuma, T; Sengoku, N; Watanabe, M; Yoshimura, N | 1 |
| Campone, M; Eierman, W; Greil, R; Kaufman, B; Lane, SR; Lin, NU; Rubin, SD; Steplewski, K; Winer, EP; Zembryki, D | 1 |
| Azzariti, A; Cantore, M; Cassano, G; Colabufo, NA; Gasparre, G; Iannelli, G; Panaro, MA; Paradiso, A; Porcelli, L; Quatrale, AE; Tommasi, S | 1 |
| Ju, RJ; Li, N; Li, RJ; Lu, WL; Wang, XX; Wang, ZH; Yao, HJ; Yu, Y; Zhang, L; Zhang, Y; Zhou, J | 1 |
| Jubin, RG; Liu, LF; Lyu, YL; Pestka, S; Tsai, YC; Wan, S | 1 |
| Fukuda, K; Imai, Y; Ueda, Y; Yamagishi, H; Yoshimori, M | 1 |
| Assaraf, YG; Goler-Baron, V | 1 |
| Allen, JD; Koomen, GJ; Lakhai, JM; Reid, G; Schellens, JH; Schinkel, AH; van der Valk, M; van Loevezijn, A; van Tellingen, O | 1 |
| Chappell, SC; Errington, RJ; Feeney, GP; Marquez, N; Smith, PJ; Wiltshire, M | 1 |
| Huang, F; Lu, HZ; Wu, DL | 1 |
| Nyormoi, O; Satoh, TH; Surmacz, TA; Whitacre, CM | 1 |
| Aller, A; Andreotti, P; Caceres, G; Jiao, JA; Wong, H; Zankina, R; Zhu, X | 1 |
| Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL | 1 |
| Doi, S; Ikegami, Y; Kitazaki, T; Kohno, S; Mizuta, Y; Murase, K; Nakamura, Y; Nakatomi, K; Oka, M; Ross, DD; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
| Bates, SE; Blayney, M; Mistry, P; Morisaki, K; Polgar, O; Robey, RW; Steadman, K | 1 |
| Bjornsti, MA; de Jong, LA; Jansen, LE; Pluim, D; Schellens, JH; van Eijndhoven, MA; van Waardenburg, RC; Verseyden, C | 1 |
| Asada, S; Imai, Y; Ishikawa, E; Sugimoto, Y | 1 |
| Daoud, SS; Mixter, P; Redkar, A | 1 |
| Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
| Akbas, SH; Ozben, T; Timur, M | 2 |
| Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC | 1 |
| Davidson, NE; Gradishar, WJ; Kennedy, MJ; Lord, RS; O'Neill, A; Stewart, JA; Wolff, AC; Wood, WC | 1 |
| Dai, Y; Gupta, A; Hebert, MF; Mao, Q; Ross, DD; Thummel, KE; Unadkat, JD; Vethanayagam, RR | 1 |
| McGuire, WP | 1 |
| Beijnen, JH; Borst, P; Breedveld, P; Cipriani, G; Dahlhaus, F; de Wolf, CJ; Jansen, G; Kuil, A; Pluim, D; Scheffer, GL; Schellens, JH; van Eijndhoven, MA | 1 |
| AFlint, JA; Ardelt, B; Coradetti, T; Darzynkiewicz, Z; Davidowitz, H; Huang, Z; Lin, X; Mandecki, W; MKopacka, WM; Wang, Z | 1 |
| Grohe, C; Hedde, JP; Kleinschmidt, R; Ko, YD; Lange, O; Losem, C; Metzler, U; Neuhaus, T; Schmidt-Wolf, IG; Schüller, H; Stier, S | 1 |
| Chappell, MJ; Cheung, SY; Errington, RJ; Evans, ND; Godfrey, KR; Smith, PJ | 1 |
| Fields, SZ; Hargis, JB; Lilenbaum, RC; Miller, AA; Rosner, GL; Schilsky, RL | 1 |
| Cowan, KH; Horton, JK; Schneider, E; Yang, CJ | 1 |
| Ara, G; Eder, JP; Herman, TS; Holden, SA; Korbut, T; Schwartz, GN; Teicher, BA | 1 |
| Hickish, T; Joel, S; Mainwaring, PN; Nicolson, MC; Penson, R; Slevin, M; Smith, IE | 1 |
| Chang, AY | 1 |
| Adler, H; Buckley, M; Cho, J; Dar, K; Fry, D; Hochster, H; Kim, T; Liebes, L; Pease, D; Potmesil, M; Zeleniuch-Jacquotte, A | 1 |
| Ansari, R; Bitran, JD; Fasanmade, AA; Fleming, GF; Hoffman, PC; Klepsch, A; Kugler, JW; Malone, D; Ratain, MJ; Vokes, EE | 1 |
| Frei, E | 1 |
| Burris, H; Fields, S; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; van Beurden, V; van den Burg, ME; Verweij, J; von Hoff, DD | 1 |
| Canellos, G; Cirrincione, CT; Henderson, IC; Levine, EG; Norton, L; Szatrowski, TP | 1 |
| Bates, SE; Brangi, M; Ciotti, M; Fojo, T; Kohlhagen, G; Litman, T; Nishiyama, K; Pommier, Y; Robey, R; Takimoto, C | 1 |
| Bianco, AR; Caputo, R; Ciardiello, F; De Laurentiis, M; De Placido, S; Pomatico, G; Tortora, G | 1 |
| Allen, JD; Dalton, WS; de Jong, MC; Maliepaard, M; Pijnenborg, AC; Ross, DD; Scheffer, GL; Schellens, JH; Scheper, RJ; Schroeijers, AB; van der Kolk, DM; van der Valk, P; van Gastelen, MA | 1 |
| Harada, M; Imai, J; Kawaguchi, T; Kiuchi, S; Okuno, S; Sakamura, Y; Tsuda, N; Tsujihara, K; Yano, S; Yano, T | 1 |
| Bally, M; Choice, E; Madden, TD; Masin, D; Redelmeier, T; Tardi, P | 1 |
| Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW | 1 |
| Chen, YC; Kuo, ML; Rocchi, E; Schneider, E; Volk, EL; Yang, CH | 1 |
| Egorin, MJ; Lüftner, DI; Natale, JJ; Possinger, K; Richter, T; Schweigert, M; Sezer, O; Zamboni, WC | 1 |
| Blank, E; Ceriani, R; Furmanski, P; Hochster, H; Kramer, E; Liebes, L; Ng, B; Wasserheit, C | 1 |
| Deertz, H; Hilfrich, J; Kieback, DG; Mesrogli, M; Oberhoff, C; Schindler, AE; Sehouli, J; Staab, HJ; van Soest, C; von Minckwitz, G; Würstlein, R | 1 |
| Bates, SE; Dean, M; Honjo, Y; Hrycyna, CA; Litman, T; Medina-Pérez, WY; Robey, RW; van de Laar, A; Yan, QW | 1 |
| Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Tsuruo, T | 1 |
| Chen, BM; Chern, JW; Leu, YL; Prijovich, ZM; Roffler, SR | 1 |
| Hudes, G | 1 |
| Beijnen, JH; Jewell, RC; Kruijtzer, CM; Paul, EM; Rosing, H; Schellens, JH; Schot, M; ten Bokkel Huinink, WW | 1 |
| Donehower, RC; Grochow, LB; Hendricks, CB; Kaufmann, SH; Rowinsky, EK | 1 |
4 review(s) available for topotecan and Breast Cancer
| Article | Year |
|---|---|
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Neoplasm Metastasis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2013 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine | 2014 |
[Drug-resistant proteins in breast cancer: recent progress in multidrug resistance].
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Mitoxantrone; Neoplasm Proteins; Topotecan; Tumor Cells, Cultured | 2003 |
The potential role of topotecan in the treatment of advanced breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Female; Humans; Neoplasm Staging; Topoisomerase I Inhibitors; Topotecan | 1997 |
13 trial(s) available for topotecan and Breast Cancer
| Article | Year |
|---|---|
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Female; Humans; In Vitro Techniques; Lapatinib; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasms; Quinazolines; Topotecan; Xenograft Model Antitumor Assays | 2008 |
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Topotecan | 2011 |
Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193.
Topics: Adenocarcinoma; Adult; Aged; Bone Neoplasms; Breast Neoplasms; DNA Topoisomerases, Type I; Doxorubicin; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Middle Aged; Soft Tissue Neoplasms; Topotecan | 2005 |
A phase I/II trial of topotecan and radiation therapy for brain metastases in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Dose-Response Relationship, Radiation; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Topotecan; Treatment Outcome | 2007 |
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Neutropenia; Recombinant Proteins; Salivary Gland Neoplasms; Stomach Neoplasms; Topotecan | 1994 |
[Topotecan--a new principle of effectiveness in oncology. 4th Salzburg Symposium on Quality of Life. 15-17 December 1995].
Topics: Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Camptothecin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Humans; Ovarian Neoplasms; Topotecan | 1996 |
Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Topotecan | 1997 |
Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Autoantibodies; Autoantigens; Biomarkers; Biopsy; Breast Neoplasms; Cell Line; DNA Topoisomerases, Type I; Endometrial Neoplasms; Esophageal Neoplasms; Female; Gastrointestinal Neoplasms; HeLa Cells; Humans; Lung Neoplasms; Nuclear Proteins; Ovarian Neoplasms; Pancreatic Neoplasms; Scleroderma, Systemic; Stomach Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1998 |
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Regression Analysis; Topotecan; Treatment Outcome | 1998 |
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Fatigue; Female; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Topotecan; Treatment Outcome | 1998 |
Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Salvage Therapy; Survival Analysis; Topotecan | 1999 |
Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study.
Topics: Adult; Aged; Brain Neoplasms; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; Survival Rate; Topotecan; Treatment Outcome | 2001 |
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Topics: Acridines; Administration, Oral; Adult; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Breast Neoplasms; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Isoquinolines; Middle Aged; Neoplasm Proteins; Tetrahydroisoquinolines; Topotecan | 2002 |
52 other study(ies) available for topotecan and Breast Cancer
| Article | Year |
|---|---|
Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Cell Survival; Diethylstilbestrol; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogens; Estrone; Female; Humans; K562 Cells; Kinetics; Mitoxantrone; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Tamoxifen; Topotecan; Tumor Cells, Cultured | 2003 |
Laurenditerpenol, a new diterpene from the tropical marine alga Laurenciaintricata that potently inhibits HIF-1 mediated hypoxic signaling in breast tumor cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Diterpenes; DNA-Binding Proteins; Dose-Response Relationship, Drug; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Mitochondria; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Rhodophyta; Stereoisomerism; Transcription Factors | 2004 |
Synthesis and antiproliferative evaluation of 3-phenylquinolinylchalcone derivatives against non-small cell lung cancers and breast cancers.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chalcone; Drug Screening Assays, Antitumor; Female; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Quinolines | 2013 |
Functional daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor alpha; Female; Humans; Isoflavones; MCF-7 Cells; Mice, Nude; Neoplasm Proteins; Topotecan; Tumor Burden | 2019 |
Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Female; Humans; Infusions, Intraventricular; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Middle Aged; Progression-Free Survival; Radiotherapy, Adjuvant; Retrospective Studies; Time Factors; Topoisomerase I Inhibitors; Topotecan | 2020 |
Synchronized Ratiometric Codelivery of Metformin and Topotecan through Engineered Nanocarrier Facilitates In Vivo Synergistic Precision Levels at Tumor Site.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Humans; Kaplan-Meier Estimate; Lipid Bilayers; Metformin; Mice; Mice, Inbred BALB C; Nanoparticles; Porosity; Silicon Dioxide; Topotecan | 2018 |
Ultrasound-Triggered Spatiotemporal Delivery of Topotecan and Curcumin as Combination Therapy for Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Curcumin; Drug Delivery Systems; Female; Humans; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Nanostructures; Neoplasms, Experimental; Topotecan; Ultrasonics | 2019 |
Leptomeningeal carcinomatosis from breast cancer treated with intrathecal topotecan with concomitant intravenous eribulin.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Furans; Humans; Injections, Intravenous; Injections, Spinal; Ketones; Meningeal Carcinomatosis; Middle Aged; Topotecan | 2014 |
Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicity.
Topics: Animals; Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Carcinogenesis; CD24 Antigen; Cell Adhesion Molecules; Cell Line, Tumor; Epithelial Cell Adhesion Molecule; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mice, Nude; Neoplasm Proteins; Receptor, ErbB-2; Topotecan | 2015 |
MHP-1 inhibits cancer metastasis and restores topotecan sensitivity via regulating epithelial-mesenchymal transition and TGF-β signaling in human breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cordyceps; Epithelial-Mesenchymal Transition; Female; Humans; MCF-7 Cells; Neoplasm Metastasis; Plant Extracts; Polysaccharides; Topotecan | 2016 |
[A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Combinations; Female; Humans; Mitoxantrone; Neoplasm Staging; Oxonic Acid; Paclitaxel; Tegafur; Time Factors; Tomography, X-Ray Computed; Topotecan | 2008 |
MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biphenyl Compounds; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Doxorubicin; Drug Synergism; Female; Genomics; Humans; Irinotecan; Kinetics; Multidrug Resistance-Associated Proteins; Necrosis; Neoplasm Proteins; Signal Transduction; Tetrahydroisoquinolines; Topotecan | 2011 |
Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Liposomes; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Skin Neoplasms; Topotecan | 2012 |
Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Genes, MHC Class I; Histocompatibility Antigens Class I; Humans; Interferon-beta; Interleukin-6; Interleukin-8; NF-kappa B; Signal Transduction; Topotecan; Tumor Necrosis Factor-alpha | 2012 |
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Topics: Androstadienes; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Topotecan; Wortmannin | 2012 |
Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics.
Topics: Aminoacridines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epithelial Cells; Female; Humans; Lysosomes; Macrolides; Neoplasm Proteins; Photosensitizing Agents; Protein Transport; Topotecan; Transcription Factors | 2012 |
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Indoles; Intestines; Mice; Mitoxantrone; Mycotoxins; Neoplasm Proteins; Topotecan; Transfection; Tumor Cells, Cultured; Vincristine | 2002 |
Tracking the cell cycle origins for escape from topotecan action by breast cancer cells.
Topics: Antineoplastic Agents; Biological Transport; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Female; Humans; Kinetics; Topotecan; Tumor Suppressor Protein p53 | 2003 |
Inhibition of focal adhesion kinase by antisense oligonucleotides enhances the sensitivity of breast cancer cells to camptothecins.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 3; Caspase 9; Caspases; Cell Adhesion; Enzyme Activation; Enzyme Precursors; Female; Fibronectins; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotides, Antisense; Poly(ADP-ribose) Polymerases; Protein-Tyrosine Kinases; Sensitivity and Specificity; Topotecan; Tumor Cells, Cultured; Tumor Protein, Translationally-Controlled 1 | 2003 |
Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Luciferases; Male; Mice; Prostatic Neoplasms; Topotecan; Treatment Outcome; Tumor Cells, Cultured | 2003 |
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured | 2003 |
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Topics: Aminocoumarins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Coumarins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Novobiocin; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2004 |
Pheophorbide a is a specific probe for ABCG2 function and inhibition.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Chlorophyll; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins; Quinolines; Staurosporine; Topotecan | 2004 |
Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cisplatin; Colonic Neoplasms; Cytarabine; DNA; DNA Adducts; DNA Topoisomerases, Type I; Drug Synergism; Enzyme Inhibitors; Female; Humans; Models, Molecular; Ovarian Neoplasms; Platinum Compounds; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2004 |
Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Northern; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Tamoxifen; Topotecan; Transduction, Genetic | 2005 |
Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01.
Topics: Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Carcinoma; Cell Cycle; Cell Proliferation; Epithelial Cells; Female; Genes, p53; Humans; Staurosporine; Topotecan; Tumor Cells, Cultured | 2004 |
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Humans; Nitrites; Quercetin; Reactive Oxygen Species; Topotecan | 2005 |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
The effect of Topotecan on oxidative stress in MCF-7 human breast cancer cell line.
Topics: Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Survival; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; Lipid Peroxidation; Oxidative Stress; Thiobarbituric Acid Reactive Substances; Topotecan | 2005 |
Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclosporine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Immunosuppressive Agents; Mitoxantrone; Neoplasm Proteins; Sirolimus; Substrate Specificity; Tacrolimus; Topotecan | 2006 |
Is it time for some new approaches for treating advanced ovarian cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Multicenter Studies as Topic; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Failure | 2006 |
The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Cell Line; Cell Line, Tumor; Dogs; Female; Folic Acid; Humans; Hydrogen-Ion Concentration; Kinetics; Liver; Methotrexate; Mitoxantrone; Neoplasm Proteins; Rabbits; Resveratrol; Stilbenes; Topotecan | 2007 |
Microtransponders, the miniature RFID electronic chips, as platforms for cell growth in cytotoxicity assays.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Transitional Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cost Control; Drug Screening Assays, Antitumor; Electronics; Humans; Lab-On-A-Chip Devices; Laser Scanning Cytometry; Lung Neoplasms; Microchip Analytical Procedures; Microscopy, Fluorescence; Mitoxantrone; Radio Waves; Ribonucleases; Topotecan | 2006 |
Exploration of the intercellular heterogeneity of topotecan uptake into human breast cancer cells through compartmental modelling.
Topics: Biological Transport; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Humans; Hydrolysis; Kinetics; Least-Squares Analysis; Mathematical Computing; Models, Biological; Nonlinear Dynamics; Software; Topotecan | 2008 |
Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
Topics: Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cell Survival; DNA Topoisomerases, Type I; Drug Resistance; Female; Humans; Mitoxantrone; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1995 |
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
Topics: Adenocarcinoma; Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Drug Synergism; Female; Fibrosarcoma; Humans; Indazoles; Male; Mice; Mice, Inbred C3H; Novobiocin; Topotecan; Tumor Cells, Cultured | 1993 |
Therapeutic innovation: the up-front window.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Child; Clinical Trials as Topic; Humans; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Topotecan | 1998 |
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Survival; DNA Damage; Drug Resistance, Multiple; Epirubicin; Female; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Microscopy, Confocal; Mitoxantrone; Polymerase Chain Reaction; Topotecan; Tumor Cells, Cultured | 1999 |
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carboplatin; Cell Division; Cell Line; Cell Line, Transformed; Cell Survival; Cisplatin; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; Docetaxel; Doxorubicin; Epithelial Cells; Etoposide; Female; Genes, erbB-2; Humans; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Receptor, ErbB-2; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Inbred BALB C; Mitoxantrone; Neoplasm Proteins; Topotecan; Tumor Cells, Cultured | 2000 |
Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128).
Topics: Animals; Breast Neoplasms; Camptothecin; Cell Cycle; Chromatography, Gel; Chromatography, High Pressure Liquid; Dextrans; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Female; HeLa Cells; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Prodrugs; Rats; Rats, Wistar; Time Factors; Tissue Distribution; Topotecan; Tumor Cells, Cultured | 2000 |
Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Drug Carriers; Female; Humans; Leukemia L1210; Liposomes; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Mice, SCID; Survival Rate; Topotecan; Transplantation, Heterologous | 2000 |
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Temozolomide; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Humans; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Neoplasm Proteins; Topotecan; Tumor Cells, Cultured | 2000 |
The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid.
Topics: Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Topotecan | 2001 |
Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bone Marrow; Breast Neoplasms; Cell Division; Combined Modality Therapy; Drug Synergism; Enzyme Inhibitors; Female; Humans; Immunoglobulin G; Immunotoxins; Mice; Mice, Nude; Pentetic Acid; Radiation Tolerance; Radioimmunotherapy; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2001 |
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, MDR; Genetic Vectors; HeLa Cells; Humans; Irinotecan; Mitoxantrone; Mutation; Neoplasm Proteins; Rhodamine 123; RNA, Messenger; Substrate Specificity; Topotecan; Transfection; Tumor Cells, Cultured; Vaccinia virus | 2001 |
Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrone; Female; Flow Cytometry; Humans; Irinotecan; K562 Cells; Mitoxantrone; Neoplasm Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection | 2002 |
Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Drug Stability; Female; Glucuronides; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Prodrugs; Sex Factors; Solubility; Topotecan; Tumor Cells, Cultured; Weight Loss; Xenograft Model Antitumor Assays | 2002 |
Boosting bioavailability of topotecan: what do we gain?
Topics: Acridines; Administration, Oral; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Intestinal Absorption; Isoquinolines; Neoplasm Proteins; Tetrahydroisoquinolines; Topoisomerase I Inhibitors; Topotecan | 2002 |
Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
Topics: Acute Disease; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Camptothecin; CHO Cells; Cricetinae; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Flow Cytometry; Leukemia; Membrane Glycoproteins; Quinidine; Topotecan; Tumor Cells, Cultured | 1992 |